ISPE Good Practice Guide - Containment for Potent Compounds 2022 PDF

Full title and description

ISPE Good Practice Guide - Containment for Potent Compounds (2022). A comprehensive industry guide produced by the International Society for Pharmaceutical Engineering (ISPE) that consolidates engineering, toxicology and occupational-hygiene approaches to control operator and cross‑contamination risk when handling highly potent drug substances and products. The Guide presents containment technologies, verification and performance assessment methods, cleaning and waste treatment approaches, and lifecycle/GMP considerations for modern pharmaceutical development and manufacturing.

Abstract

This Good Practice Guide explains the principles and practical implementation of containment for potent compounds across the drug lifecycle. It summarises toxicological concepts used to define safe working or residue limits, describes typical exposure mechanisms, presents engineering controls (isolators, process interfaces, airlocks, filtration systems and other containment technologies), and provides guidance on containment strategy development, verification, cleaning, spill response and GMP alignment. The Guide was developed by a multinational team of engineers, toxicologists, hygienists and analysts to consolidate dispersed knowledge into a single practical reference.

General information

• Status: Published (industry Good Practice Guide).
• Publication date: December 2022.
• Publisher: International Society for Pharmaceutical Engineering (ISPE).
• ICS / categories: ICS 11.120 (Pharmaceuticals) and related health/medical technology categories (containment, occupational safety, cleanroom/containment engineering).
• Edition / version: Good Practice Guide — 2022 edition (original ISPE Good Practice Guide publication).
• Number of pages: 258 pages.

Scope

The Guide covers containment for highly potent active pharmaceutical ingredients (APIs), intermediates and potent formulations across development and commercial manufacture. Topics include derivation and use of safe working/residue limits, occupational exposure control strategies, engineering containment technologies and interfaces, containment performance assessment and verification methods, cleaning and decontamination, unplanned emissions and spill recovery, lifecycle and GMP considerations, and development of a risk‑based containment strategy for shared and dedicated facilities. It is intended for application across small and large‑molecule processes and for equipment and facility design, operation and validation.

Key topics and requirements

• Background on potency, mechanisms of exposure and toxicological bases for safe limits (HBEL/PDE concepts).
• Risk‑based containment strategy development and decision criteria for dedicated vs multi‑product facilities.
• Engineering controls and technologies: isolators, gloveboxes, process interfaces, transfer ports, airlocks and filtration systems.
• Containment performance assessment, verification testing and acceptance criteria.
• Cleaning, decontamination and residue management including links to cleaning validation and HBEL‑based limits.
• GMP alignment, lifecycle management of containment systems, documentation and change control considerations.
• Unplanned emission/spill response, waste handling and occupational hygiene measures (PPE as last barrier).
• Practical examples, photographs and vendor/technology overviews to aid design and specification decisions.

Typical use and users

Primary users: pharmaceutical engineers, facility designers, process development and manufacturing leads, industrial hygienists/toxicologists, quality and regulatory professionals, validation specialists, and suppliers of containment equipment. Typical uses: developing containment strategies, specifying containment equipment and interfaces, designing verification plans, setting cleaning and residue limits informed by health‑based exposure limits, training and cross‑functional alignment on containment best practice.

Related standards

Key regulatory and consensus documents referenced or used in conjunction with this Guide include the EMA guideline on setting health‑based exposure limits for shared facilities, PIC/S aide‑memoire and Q&A on HBELs/inspection of HBEL assessments, ASTM guidance on derivation of Health‑Based Exposure Limits (E3219), and healthcare/handling standards such as USP General Chapter <800> for hazardous drugs (where relevant to occupational protection). These documents provide complementary toxicological, regulatory and technical detail for HBEL derivation, cleaning validation and inspection expectations.

Keywords

containment, potent compounds, highly potent APIs, HBEL, PDE, occupational exposure, isolators, process interfaces, cross‑contamination, cleaning validation, verification testing, GMP, risk‑based containment, industrial hygiene.

FAQ

Q: What is this standard?

A: It is an ISPE Good Practice Guide (industry guidance document) titled "Containment for Potent Compounds" published by ISPE in December 2022 that consolidates engineering, toxicology and operational best practices for controlling exposure to highly potent pharmaceutical compounds.

Q: What does it cover?

A: It covers toxicological bases for safe limits (HBEL/PDE concepts), containment technologies and interfaces (isolators, airlocks, filtration), containment performance assessment and verification, cleaning/decontamination and residue management, unplanned emission/spill response, lifecycle and GMP considerations, and development of a risk‑based containment strategy for manufacturing facilities.

Q: Who typically uses it?

A: Pharmaceutical engineers, process and facility designers, industrial hygienists/toxicologists, quality/regulatory and validation teams, and containment equipment suppliers use the Guide for design, specification, risk assessment and verification of containment for potent compounds.

Q: Is it current or superseded?

A: The Guide was published in December 2022 and is the ISPE Good Practice Guide edition of that year. At the time of this summary there is no ISPE‑published superseding edition listed on the ISPE guidance documents and publications index; users should confirm on ISPE or with ISPE member services for any updates or translations issued after December 2022.

Q: Is it part of a series?

A: It is part of ISPE's Good Practice Guide series (a collection of industry guidance documents covering topics across pharmaceutical engineering and operations). ISPE also publishes other containment and related reference materials used by regional CoPs and working groups.

Q: What are the key keywords?

A: Containment, potent compounds, HBEL/PDE, isolators, cross‑contamination, cleaning validation, verification, occupational exposure, GMP.